A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.
Oral daily and weekly bisphosphonates represent the current mainstay of treatment for postmenopausal osteoporosis (PMO). However, the inconvenience of frequent dosing is known to negatively affect adherence to therapy in the long term. This has prompted the development of convenient oral bisphosphon...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2006
|
| _version_ | 1797059521294630912 |
|---|---|
| author | Reginster, J Felsenberg, D Cooper, C Stakkestad, J Miller, P Kendler, D Adami, S McClung, MR Bolognese, M Civitelli, R Dumont, E Bonvoisin, B Recker, R Delmas, P |
| author_facet | Reginster, J Felsenberg, D Cooper, C Stakkestad, J Miller, P Kendler, D Adami, S McClung, MR Bolognese, M Civitelli, R Dumont, E Bonvoisin, B Recker, R Delmas, P |
| author_sort | Reginster, J |
| collection | OXFORD |
| description | Oral daily and weekly bisphosphonates represent the current mainstay of treatment for postmenopausal osteoporosis (PMO). However, the inconvenience of frequent dosing is known to negatively affect adherence to therapy in the long term. This has prompted the development of convenient oral bisphosphonate regimens that feature simple, less frequent dosing schedules. Such regimens require high potency agents, which can be given at low effective doses and that also have good tolerability. Ibandronate is a potent, nitrogen-containing bisphosphonate with proven efficacy when given intermittently to estrogen-depleted beagle dogs, rats and cynomolgus monkeys. Clinically, a pivotal prospective study has established that oral ibandronate has significant vertebral fracture efficacy in PMO, whether given daily (2.5 mg) or intermittently (20 mg every other day for 12 doses every 3 months; extended between-dose interval>2 months). Both oral regimens were well tolerated, which is noteworthy as patients with a history of gastrointestinal (GI) disturbance were not specifically excluded. As a result of these findings, a large, multinational, randomized, double-blind study (Monthly Oral iBandronate In LadiEs: MOBILE) is currently exploring the non-inferiority of once-monthly oral ibandronate (100 or 150 mg) to the oral daily ibandronate (2.5 mg) regimen with proven anti-fracture efficacy, in terms of lumbar spine bone mineral density (BMD) change. As with the trials investigating the weekly administration of other bisphosphonates, vertebral fracture efficacy will be inferred if the study demonstrates the non-inferiority of once-monthly ibandronate to the proven oral daily regimen in terms of spinal BMD change. The availability of this once-monthly ibandronate regimen is expected to offer benefits in terms of convenience (by having to follow dosing recommendations once a month vs. once daily or weekly) and potentially tolerability (by reducing the potential for upper GI irritation that can result from frequent, repeated exposure). Greater convenience and tolerability may enhance the therapy adherence and, hence, improve long-term therapeutic outcomes in PMO. |
| first_indexed | 2024-03-06T20:05:28Z |
| format | Journal article |
| id | oxford-uuid:28c2adfb-6660-439e-847d-a0a9763c3a1c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:05:28Z |
| publishDate | 2006 |
| record_format | dspace |
| spelling | oxford-uuid:28c2adfb-6660-439e-847d-a0a9763c3a1c2022-03-26T12:14:56ZA new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:28c2adfb-6660-439e-847d-a0a9763c3a1cEnglishSymplectic Elements at Oxford2006Reginster, JFelsenberg, DCooper, CStakkestad, JMiller, PKendler, DAdami, SMcClung, MRBolognese, MCivitelli, RDumont, EBonvoisin, BRecker, RDelmas, POral daily and weekly bisphosphonates represent the current mainstay of treatment for postmenopausal osteoporosis (PMO). However, the inconvenience of frequent dosing is known to negatively affect adherence to therapy in the long term. This has prompted the development of convenient oral bisphosphonate regimens that feature simple, less frequent dosing schedules. Such regimens require high potency agents, which can be given at low effective doses and that also have good tolerability. Ibandronate is a potent, nitrogen-containing bisphosphonate with proven efficacy when given intermittently to estrogen-depleted beagle dogs, rats and cynomolgus monkeys. Clinically, a pivotal prospective study has established that oral ibandronate has significant vertebral fracture efficacy in PMO, whether given daily (2.5 mg) or intermittently (20 mg every other day for 12 doses every 3 months; extended between-dose interval>2 months). Both oral regimens were well tolerated, which is noteworthy as patients with a history of gastrointestinal (GI) disturbance were not specifically excluded. As a result of these findings, a large, multinational, randomized, double-blind study (Monthly Oral iBandronate In LadiEs: MOBILE) is currently exploring the non-inferiority of once-monthly oral ibandronate (100 or 150 mg) to the oral daily ibandronate (2.5 mg) regimen with proven anti-fracture efficacy, in terms of lumbar spine bone mineral density (BMD) change. As with the trials investigating the weekly administration of other bisphosphonates, vertebral fracture efficacy will be inferred if the study demonstrates the non-inferiority of once-monthly ibandronate to the proven oral daily regimen in terms of spinal BMD change. The availability of this once-monthly ibandronate regimen is expected to offer benefits in terms of convenience (by having to follow dosing recommendations once a month vs. once daily or weekly) and potentially tolerability (by reducing the potential for upper GI irritation that can result from frequent, repeated exposure). Greater convenience and tolerability may enhance the therapy adherence and, hence, improve long-term therapeutic outcomes in PMO. |
| spellingShingle | Reginster, J Felsenberg, D Cooper, C Stakkestad, J Miller, P Kendler, D Adami, S McClung, MR Bolognese, M Civitelli, R Dumont, E Bonvoisin, B Recker, R Delmas, P A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. |
| title | A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. |
| title_full | A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. |
| title_fullStr | A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. |
| title_full_unstemmed | A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. |
| title_short | A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. |
| title_sort | new concept for bisphosphonate therapy a rationale for the development of monthly oral dosing of ibandronate |
| work_keys_str_mv | AT reginsterj anewconceptforbisphosphonatetherapyarationaleforthedevelopmentofmonthlyoraldosingofibandronate AT felsenbergd anewconceptforbisphosphonatetherapyarationaleforthedevelopmentofmonthlyoraldosingofibandronate AT cooperc anewconceptforbisphosphonatetherapyarationaleforthedevelopmentofmonthlyoraldosingofibandronate AT stakkestadj anewconceptforbisphosphonatetherapyarationaleforthedevelopmentofmonthlyoraldosingofibandronate AT millerp anewconceptforbisphosphonatetherapyarationaleforthedevelopmentofmonthlyoraldosingofibandronate AT kendlerd anewconceptforbisphosphonatetherapyarationaleforthedevelopmentofmonthlyoraldosingofibandronate AT adamis anewconceptforbisphosphonatetherapyarationaleforthedevelopmentofmonthlyoraldosingofibandronate AT mcclungmr anewconceptforbisphosphonatetherapyarationaleforthedevelopmentofmonthlyoraldosingofibandronate AT bolognesem anewconceptforbisphosphonatetherapyarationaleforthedevelopmentofmonthlyoraldosingofibandronate AT civitellir anewconceptforbisphosphonatetherapyarationaleforthedevelopmentofmonthlyoraldosingofibandronate AT dumonte anewconceptforbisphosphonatetherapyarationaleforthedevelopmentofmonthlyoraldosingofibandronate AT bonvoisinb anewconceptforbisphosphonatetherapyarationaleforthedevelopmentofmonthlyoraldosingofibandronate AT reckerr anewconceptforbisphosphonatetherapyarationaleforthedevelopmentofmonthlyoraldosingofibandronate AT delmasp anewconceptforbisphosphonatetherapyarationaleforthedevelopmentofmonthlyoraldosingofibandronate AT reginsterj newconceptforbisphosphonatetherapyarationaleforthedevelopmentofmonthlyoraldosingofibandronate AT felsenbergd newconceptforbisphosphonatetherapyarationaleforthedevelopmentofmonthlyoraldosingofibandronate AT cooperc newconceptforbisphosphonatetherapyarationaleforthedevelopmentofmonthlyoraldosingofibandronate AT stakkestadj newconceptforbisphosphonatetherapyarationaleforthedevelopmentofmonthlyoraldosingofibandronate AT millerp newconceptforbisphosphonatetherapyarationaleforthedevelopmentofmonthlyoraldosingofibandronate AT kendlerd newconceptforbisphosphonatetherapyarationaleforthedevelopmentofmonthlyoraldosingofibandronate AT adamis newconceptforbisphosphonatetherapyarationaleforthedevelopmentofmonthlyoraldosingofibandronate AT mcclungmr newconceptforbisphosphonatetherapyarationaleforthedevelopmentofmonthlyoraldosingofibandronate AT bolognesem newconceptforbisphosphonatetherapyarationaleforthedevelopmentofmonthlyoraldosingofibandronate AT civitellir newconceptforbisphosphonatetherapyarationaleforthedevelopmentofmonthlyoraldosingofibandronate AT dumonte newconceptforbisphosphonatetherapyarationaleforthedevelopmentofmonthlyoraldosingofibandronate AT bonvoisinb newconceptforbisphosphonatetherapyarationaleforthedevelopmentofmonthlyoraldosingofibandronate AT reckerr newconceptforbisphosphonatetherapyarationaleforthedevelopmentofmonthlyoraldosingofibandronate AT delmasp newconceptforbisphosphonatetherapyarationaleforthedevelopmentofmonthlyoraldosingofibandronate |